Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > San Antonio Breast Cancer Symposum (SABCS) December 2022

<< Previous

Bullboard Posts

Next >>

Post by pelabooston Oct 01, 2023 2:36pm

261 Views

Post# 35664039

San Antonio Breast Cancer Symposum (SABCS) December 2022

I was reading a release dated December 8, 2022 that pertains to the bridging study. Worth reading.

Of Note.

Thirteen of 14 (93%) evaluable patients achieved disease control, with 12 (86%) showing tumor shrinkage.

One patient achieving a PR at week 8 has maintained the PR through week 48 and remains on study.

The data cut-off date was September 26, 2022.

Adlai Nortye has done some top shelf work.

<< Previous

Bullboard Posts

Next >>

First Nations contributions attract investor interest